Jangir Exports Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Jangir Exports Pharmaceutical Export Portfolio Dataset — 3 Products, $695.7K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Jangir Exports — Pharmaceutical Exporter Profile (2026) | 3 Products, $695.7K Trade | TransData Nexus

Jangir Exports

Indian Pharmaceutical Exporter · Ayurvedic & Herbal Products Specialist · $695.7K Total Trade · DGFT Verified

Jangir Exports is an Indian pharmaceutical exporter with a total trade value of $695.7K across 3 products in 1 therapeutic categories. Based on 914 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Herbal ($640.6K), Kwatha ($50.3K), Gutika ($4.9K).

Jangir Exports — Export Portfolio & Destination Treemap

Jangir Exports pharmaceutical export portfolio — 3 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Jangir Exports? — Company Overview & Market Position

Jangir Exports is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2017, the company is headquartered in New Delhi, India. It operates as a proprietorship firm under the leadership of CEO Ram Lal Jangir. The company has a workforce of approximately 26 to 50 employees. Jangir Exports' registered address is A-39, A-40, 1st Floor, Ambey Garden, 60 Foot Road, Libaspur, GT Karnal Road, AG Block, G, New Delhi-110042, Delhi, India.

The company's Import Export Code (IEC) is 0500029733, and it is registered under GST No. 07AAGPJ3994E1ZL. Jangir Exports has an annual turnover ranging between 1.5 to 5 crore INR. The official website of Jangir Exports is www.jangircompany.in.

What Does Jangir Exports Export? — Product Portfolio Analysis

Top Products by Export Value

1Herbal$640.6K 2Kwatha$50.3K

Product Portfolio — Top 3 by Export Value

Jangir Exports exports 3 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Herbal	Ayurvedic & Herbal Products	$640.6K	747	3.4%	4
2	Kwatha	Ayurvedic & Herbal Products	$50.3K	157	9.4%	3
3	Gutika	Ayurvedic & Herbal Products	$4.9K	10	3.9%	6

Jangir Exports exports 3 pharmaceutical products across 1 therapeutic categories with a total export value of $695.7K. The top category is Ayurvedic & Herbal Products (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Jangir Exports — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Jangir Exports operates manufacturing facilities in New Delhi, India. The company specializes in the production of Ayurvedic and herbal pharmaceutical formulations, focusing on tablets, capsules, syrups, and injections. Specific details regarding the manufacturing plant locations, capacities, and certifications are not publicly disclosed. However, the company emphasizes its commitment to quality and compliance with international standards.

3Key Leadership

The leadership team at Jangir Exports is headed by CEO Ram Lal Jangir, who also serves as the proprietor of the company. The company's registered address is A-39, A-40, 1st Floor, Ambey Garden, 60 Foot Road, Libaspur, GT Karnal Road, AG Block, G, New Delhi-110042, Delhi, India. Specific information regarding other key executives, such as the CFO or other senior management members, is not publicly available.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Jangir Exports Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Jangir Exports primarily focuses on exporting Ayurvedic and herbal pharmaceutical formulations to various international markets. The company's total export value is $696,000 USD, with 914 shipments across three products in the Ayurvedic & Herbal Products category. The top three products exported are Herbal formulations ($641,000 USD), Kwatha ($50,000 USD), and Gutika ($5,000 USD). The company holds a 3.4% market share in Herbal formulations, a 9.4% market share in Kwatha, and a 3.9% market share in Gutika. Specific details regarding regulatory filings, approvals, and market access status in the US, EU, UK, Australia, and Japan are not publicly disclosed.

2Emerging Markets

Jangir Exports has a presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's focus on Ayurvedic and herbal products aligns with the growing demand for natural and traditional medicines in these regions. While specific details regarding WHO prequalification and other regulatory approvals are not publicly available, the company's export activities suggest an effort to meet international standards and gain access to these markets.

3Geographic Strategy

Jangir Exports — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Jangir Exports' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export data does not indicate shipments to the United States, suggesting that it may not currently have FDA approvals or registrations. This could be due to the nature of the products (Ayurvedic and herbal formulations) and the regulatory requirements for such products in the US market.

2WHO & EU GMP

Jangir Exports' export data does not provide specific information regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status. The company's focus on Ayurvedic and herbal products may require adherence to specific international standards; however, without publicly available certifications, it is challenging to assess the company's compliance with these standards.

3CDSCO & Indian Regulatory

Jangir Exports — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Jangir Exports operates in the Ayurvedic and herbal pharmaceutical sector, a niche market with several key players. While specific competitors are not identified in the available data, the company's focus on Ayurvedic and herbal formulations positions it in a competitive landscape that includes both domestic and international manufacturers. The company's export data indicates a total export value of $696,000 USD, with 914 shipments across three products, suggesting a moderate market presence.

2Key Differentiators

Jangir Exports' key differentiators include its specialization in Ayurvedic and herbal pharmaceutical formulations, catering to the growing global demand for natural and traditional medicines. The company's focus on finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, allows it to offer ready-to-use products that meet international standards. However, the company's portfolio concentration, with the top three products accounting for 100% of the export value, may limit its ability to diversify and adapt to changing market demands.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Jangir Exports as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Jangir Exports has a total export value of $696,000 USD, with 914 shipments across three products in the Ayurvedic & Herbal Products category. The top three products exported are Herbal formulations ($641,000 USD), Kwatha ($50,000 USD), and Gutika ($5,000 USD). The company holds a 3.4% market share in Herbal formulations, a 9.4% market share in Kwatha, and a 3.9% market share in Gutika. The company's export data indicates a moderate market presence, with a focus on Ayurvedic and herbal products. However, the high portfolio concentration suggests a need for diversification to enhance reliability and reduce dependency on a limited product range.

2Certifications to Verify

Importers should verify the following certifications when considering Jangir Exports as a supplier:

FDA Registration: To ensure compliance with US regulatory standards, verify the company's FDA facility registration status. This can be done by searching the FDA's Establishment Registration & Device Listing database.

WHO-GMP Certification: To confirm adherence to World Health Organization Good Manufacturing Practices, request a copy of the WHO-GMP certificate from the company.

Frequently Asked Questions — Jangir Exports

How many pharmaceutical products does Jangir Exports export from India?

Jangir Exports exports 3 pharmaceutical products across 1 therapeutic categories. The top exports are Herbal ($640.6K), Kwatha ($50.3K), Gutika ($4.9K). Total export value is $695.7K.

What is Jangir Exports's total pharmaceutical export value?

Jangir Exports's total pharmaceutical export value is $695.7K, based on 914 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Jangir Exports cover?

Jangir Exports exports across 1 therapeutic categories. The largest are Ayurvedic & Herbal Products (100.0%, 3 products).

Get Full Jangir Exports Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.